1. Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.
- Author
-
Jackson, S, Marshall, JL, Mawer, A, Lopez-Ramon, R, Harris, SA, Satti, I, Hughes, E, Preston-Jones, H, Cabrera Puig, I, Longet, S, Tipton, T, Laidlaw, S, Doherty, RP, Morrison, H, Mitchell, R, Tanner, R, Ateere, A, Stylianou, E, Wu, M-S, Fredsgaard-Jones, TPW, Breuer, J, Rapeport, G, Ferreira, VM, Gleeson, F, Pollard, AJ, Carroll, M, Catchpole, A, Chiu, C, McShane, H, COV-CHIM01 study team, Jackson, S, Marshall, JL, Mawer, A, Lopez-Ramon, R, Harris, SA, Satti, I, Hughes, E, Preston-Jones, H, Cabrera Puig, I, Longet, S, Tipton, T, Laidlaw, S, Doherty, RP, Morrison, H, Mitchell, R, Tanner, R, Ateere, A, Stylianou, E, Wu, M-S, Fredsgaard-Jones, TPW, Breuer, J, Rapeport, G, Ferreira, VM, Gleeson, F, Pollard, AJ, Carroll, M, Catchpole, A, Chiu, C, McShane, H, and COV-CHIM01 study team
- Abstract
BACKGROUND: A SARS-CoV-2 controlled human infection model (CHIM) has been successfully established in seronegative individuals using a dose of 1×101 50% tissue culture infectious dose (TCID50) pre-alpha SARS-CoV-2 virus. Given the increasing prevalence of seropositivity to SARS-CoV-2, a CHIM that could be used for vaccine development will need to induce infection in those with pre-existing immunity. Our aim was to find a dose of pre-alpha SARS-CoV-2 virus that induced infection in previously infected individuals. METHODS: Healthy, UK volunteers aged 18-30 years, with proven (quantitative RT-PCR or lateral flow antigen test) previous SARS-CoV-2 infection (with or without vaccination) were inoculated intranasally in a stepwise dose escalation CHIM with either 1×101, 1×102, 1×10³, 1×104, or 1×105 TCID50 SARS-CoV-2/human/GBR/484861/2020, the same virus used in the seronegative CHIM. Post-inoculation, volunteers were quarantined in functionally negative pressure rooms (Oxford, UK) for 14 days and until 12-hourly combined oropharyngeal-nasal swabs were negative for viable virus by focus-forming assay. Outpatient follow-up continued for 12 months post-enrolment, with additional visits for those who developed community-acquired SARS-CoV-2 infection. The primary objective was to identify a safe, well tolerated dose that induced infection (defined as two consecutive SARS-CoV-2 positive PCRs starting 24 h after inoculation) in 50% of seropositive volunteers. This study is registered with ClinicalTrials.gov (NCT04864548); enrolment and follow-up to 12 months post-enrolment are complete. FINDINGS: Recruitment commenced on May 6, 2021, with the last volunteer enrolled into the dose escalation cohort on Nov 24, 2022. 36 volunteers were enrolled, with four to eight volunteers inoculated in each dosing group from 1×101 to 1×105 TCID50 SARS-CoV-2. All volunteers have completed quarantine, with follow-up to 12 months complete. Despite dose escalation to 1×105 TCID50, we were unable to
- Published
- 2024